DLBCL
From the Journals
Radiation bridging with axi-cel appears safe in DLBCL
At final follow-up, in a case series of 12 patients with relapsed/refractory DLBCL, the best objective response rate was 81.8%, with complete...
From the Journals
Polatuzumab vedotin combo shows promise in DLBCL
Polatuzumab vedotin plus rituximab or obinutuzumab, in addition to cyclophosphamide, doxorubicin, and prednisone, showed manageable safety and...
From the Journals
Influenza vaccination status in DLBCL poorly documented
Routine outpatient vaccination screening and strategies for sharing and linking patient vaccination status could improve vaccination documentation...